Tenax Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Tenax Therapeutics, Inc. (TENX)

NEW YORK CITY, NY / ACCESS Newswire / August 12, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Tenax Therapeutics, Inc. ("Tenax Therapeutics, Inc.") (NASDAQ:TENX) concerning potential violations of the federal securities laws.

Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company announced that its Phase 3 LEVEL trial of TNX-103 failed its primary endpoint and its key secondary endpoint in patients with PH-HFpEF.

According to the Company's announcement, TNX-103 produced a placebo-adjusted improvement in six-minute walk distance of 3.5 meters -- a result that was not statistically significant -- and essentially no difference from placebo on the Kansas City Cardiomyopathy Questionnaire symptom score. Topline LEVEL data had been guided to August 2026, after previously being guided to the third quarter of 2026.

Tenax is pre-revenue. TNX-103 (levosimendan) was the Company's lead clinical program, and the LEVEL study was its pivotal Phase 3 trial in PH-HFpEF. Exploratory results reported alongside the topline data, including a 49% reduction in NT-proBNP reduction and stronger effects among patients with greater disease burden, did not alter the outcome on the pivotal endpoints. The investigation concerns whether Tenax adequately disclosed the risks tied to that program before the LEVEL results were released.

If you suffered a loss on your Tenax Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP